As the House of Representatives moved on Wednesday toward a vote to make Donald Trump the first U.S. president to be impeached twice, the Senate’s top Republican rejected Democratic calls to reconvene the chamber for an immediate trial, all but ensuring Trump will not be ousted before his term ends next week. Senate Majority Leader
The Federal Cabinet on Tuesday granted approval on filing treason case under Article 6 of the constitution against Jamiat Ulema-i-Islam-Fazl (JUI-F) leader Mufti Kifayatullah over his anti-state remarks. According to the details, Prime Minister Imran Khan chaired the federal cabinet meeting today in Islamabad. The meeting discussed overall economic and political situation of the country.
RIO DE JANEIRO: The CoronaVac COVID-19 vaccine developed by China’s Sinovac Biotech showed efficacy between 50% and 90% in Brazilian trials, Sao Paulo’s state health secretary said, and its Brazilian producer said full trial results will be released by Jan. 7. Results of trials in Brazil are known exclusively by Sao Paulo state’s Butantan Institute
BUDAPEST: Some 3,000 to 5,000 Hungarians could participate in clinical trials of Russia’s Sputnik V vaccine against COVID-19, Hungarian Human Resources Minister Miklos Kasler said on Facebook on Monday. Hungary’s plans to conduct trials of and possibly produce the Russian vaccine, an unprecedented step for an EU member state, have added to existing frictions with
Anti-inflammatory colchicine will be tested as a possible COVID-19 treatment in one of the world’s biggest trials, the study website posted on Friday, the latest effort to repurpose existing medicines to fight the pandemic. The RECOVERY trial, which is the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, will randomly allocate at
LONDON: Johnson & Johnson launched a new large-scale late-stage trial on Monday to test a two-dose regimen of its experimental COVID-19 vaccine and evaluate potential incremental benefits for the duration of protection with a second dose. The U.S. drugmaker plans to enrol up to 30,000 participants for the study and run it in parallel with